

DAFTAR PUSTAKA

- Abraham, G., Sundaram, V., Mathew, M., Leslie, N. and Sthiah, V. 2009. C-reactive protein, a valuable predictive marker in chronic kidney disease. *Saudi Journal of Kidney Diseases and Transplantation*. 20: 811-815 PMID: 19736479
- An, X., Mao, H.P., Wei, X. 2012. Elevated neutrophil to lymphocyte ratio predicts overall and cardiovascular mortality in maintenance peritoneal dialysis patients. *Int Urol Nephrol*. 44:1521–1528
- Arora, P. 2018. Chronic Kidney Disease. Available from: <https://www.medscape.com>
- Ashby, D.R., Gale, D.P., Busbridge, M., Murphy, K.G., Duncan, N.D., Cairns, T.D., Taube, D.H., Bloom, S.R., Tam, F.W., Chapman, R.S., Maxwell, P.H., Choi, P. 2009. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. *Kidney Int*. 75: 976–981
- Babitt, J.L. & Lin, H.Y. 2010. Molecular mechanisms of hepcidin regulation: Implications for the anemia of CKD. *Am J Kidney Dis*. 55: 726–741
- Babitt, J.L. & Lin, H.Y. 2012. Mechanisms of Anemia in CKD, *J Am Soc Nephrol*. 23: 1631–1634
- Barany, P., Filho, C.D. & Bergstrom, J. 1997. High c-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. *American Journal of Kidney Diseases*. Vol 29, No 4 (April): pp 565-568
- Beddhu, S., Kaysen, G.A., Yan, G. 2002. HEMO Study Group. Association of serum albumin and atherosclerosis in chronic hemodialysis patients. *Am J Kidney Dis*. 40:721–727
- Bellanti, J.A. 1985. *Immunology III*. W.B. Saunders Company, Philadelphia
- Bergstrom, J., Heimbürger, O., Lindholm, B., Qureshi, A.R. 2005. Elevated serum C-reactive protein is a strong predictor of increased mortality and low serum albumin in hemodialysis (HD) patients. *J Am Soc Nephrol*. 6:573
- Cobo, G., Lindholm, B., & Stenvinkel, P. 2018. Chronic inflammation in end-stage renal disease and dialysis. *Nephrology Dialysis Transplantation*. 33, iii35–iii40. <https://doi.org/10.1093/ndt/gfy175>
- Cohen, G. & Hörl, W.H. 2012. Immune dysfunction in uremia An update. *Toxins*. 4: 962-990 doi: 10.3390/toxins4110962
- Cooper, A.C., Mikhail, A., Lethbridge, M.W., Kemeny, D.M., Macdougall, I.C. 2003. Increased expression of erythropoiesis inhibiting cytokines (IFN-gamma, TNF-alpha, IL-10, and IL-13) by T cells in patients exhibiting a poor response to erythropoietin therapy. *J Am Soc Nephrol*. 14: 1776–1784
- Costa, E., Lima, M., Alves, J.M., Rocha, S., RochaPereira, P., Castro, E., Miranda, V., do S.F., Loureiro, A., Quintanilha, A., Belo, L., Santos-Silva. 2008. A: Inflammation, T-cell phenotype, and inflammatory cytokines in chronic kidney disease patients under hemodialysis and its relationship to resistance to recombinant human erythropoietin therapy. *J Clin Immunol*. 28: 268–275

- Coyne, D.W. 2011. Hepcidin: Clinical utility as a diagnostic tool and therapeutic target. *Kidney International*. 80: 240-4
- Daniel G, Hackam S, Anand S. Emerging risk factors for atherosclerotic disease: A critical review of the evidence. *Journal of American Heart Association*. 2003; 290: 932-40
- Daugirdas, J.T., Rocco, M., Depner, T.A., Inrig, J., Mehrotra, R., Rocco, M. V. 2015. KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 Update. *Am J Kidney Dis*. 66(5):884–930
- Den Hoedt, C.H., Bots, M.L., Grooteman, M.P.C., van der Weerd, N.C., Mazairac, A.H.A., Penne, E.L., *et al.* 2013. Online hemodiafiltration reduces systemic inflammation compared to low-flux hemodialysis. *Kidney International*. 86, 423–432; doi:10.1038/ki.2014.9
- Descamps-Latscha, B., Herbelin, A., Nguyen, A.T. 1995. Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis Relationships with activation markers of T cells, B cells, and monocytes. *J Immunol*. 154(2):882–892
- Del Vecchio, L., Cavalli, A., Pozzoni, P. & Locatelli, F. 2008. Recombinant human epoetin beta in the treatment of renal anemia. *Therapy*. 5(1), 91–98
- Del Vecchio, L., Pozzoni, P., Andrulli, S., Locatelli, F. 2005. Inflammation and resistance to treatment with recombinant human erythropoietin. *J Ren Nutr*, 15: 137–141
- Dahlan, S.M. 2013. Besar sampel dan cara pengambilan sampel. *Penelitian Kedokteran dan Kesehatan*. Jakarta : Salemba Medika
- Drueke, T. 2001. Hyporesponsiveness to recombinant human erythropoietin. *Nephrol Dial Transplant*. 16: 25–28
- Eknoyan, G., Latos, D.L., Lindberg, J. 2003. Practice recommendations for the use of L -carnitine in dialysis-related carnitine disorder. National Kidney Foundation Carnitine Consensus Conference. *Am J Kidney Dis*. 41: 868–876
- Eloueyk, A. K., Alameddine, R. Y., Osta, B. A., & Awad, D. M. 2019. Correlations between serum inflammatory markers and comorbidities in patients with endstage renal disease. *Journal of Taibah University Medical Sciences*. 14(6), 547– 552. <https://doi.org/10.1016/j.jtumed.2019.10.003>
- Falda, U., Rahmawati, F & Irijanto, F. 2016. Evaluasi efek ACE Inhibitor terhadap respon terapi erythropoiesis stimulating agent pada pasien hemodialisis dengan anemia di RS UGM Yogyakarta. *Tesis*. S2 Ilmu Farmasi. UGM.
- Fonseca, L.A.M., Sumita, N.M., Duarte, N.J.C., Lichtenstein, A., Duarte, A.J.S. 2013. C-reactive protein: clinical applications and proposals for a rational use. *Rev Assoc Med Bras*. 59(1):85–92. Available from: [http://dx.doi.org/10.1016/S2255-4823\(13\)70434-X](http://dx.doi.org/10.1016/S2255-4823(13)70434-X)
- Kaynar, K., Ozkan, G., Erem, C., Gul, S., Yilmaz, M., Sonmez, B., Ozdemir, F., Ulusoy, S. 2007. An unusual etiology of erythropoietin resistance: hyperthyroidism. *Ren Fail*. 29: 759–761

- Kocyigit, I., Eroglu, E., Unal, A. 2013. Role of Neutrophil/Lymphocyte Ratio in Prediction of Disease Progression in Patients with Stage-4 Chronic Kidney Disease. *Journal of Nephrology*. 26, 358-365
- Kemenkes. 2017. Situasi Penyakit Ginjal Kronik. *Pusat Data dan Informasi Kemenkes RI*. Hal.8
- Kilpatrick, R.D., Critchlow, C.W., Fishbane, S., Besarab, A., Stehman-Breen, C., Krishnan, M., Bradbury, B.D. 2008. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. *Clin J Am Soc Nephrol*. 3: 1077–1083
- Kurts, C., Panzer, U., Anders, H.J. and Rees, A.J. 2013. The immune system and kidney disease: basic concepts and clinical implications. *Nature Review Immunology*. 13:738-753 doi: 10.1038/nri3523 7
- Gabay, C., Kushner, I. 1999. Acute-phase proteins and other systemic responses to inflammation. *N Engl J Med*. 340:448-454
- Gambino, R. 1997. C-reactive protein-undervalued, underutilized. *Clinical Chemistry*. Vol 43. No. 11
- Ganz, T., Olbina, G., Girelli, D., Nemeth, E., Westerman, M. 2008. Immunoassay for human serum hepcidin. *Blood*. 112: 4292–4297
- Gilbertson, D.T., Peng, Y., Arneson, T.J., Dunning, S., Collins, A.J. 2013. Comparison of methodologies to define hemodialysis patients hyporesponsive to epoetin and impact on counts and characteristics. *BMC Nephrol*. 14:44
- Goldstein-Fuchs, D. & LaPierre, A.M. 2014. Nutrition and Kidney Disease. In: Gilbert GJ, Weiner ME. Editors. *National Kidney Foundation's Primer on Kidney Diseases*. Philadelphia; Elseiver Saunderz. P:467-474
- Groopman, J.E. & Itri, L.M. 1999. Chemotherapy-induced anemia in adults: Chemotherapy-induced anemia in adults: incidence and treatment. *Journal of the National Cancer Institute*. 6;91(19):1616-34
- Gürel, A., Doğan, A., Çeliker, H., Ulu, R., Yilit, I. P., & Aygen, B. 2015. Neutrophil to lymphocyte and platelet to lymphocyte ratios in peritoneal dialysis-related peritonitis. *Turkish Nephrology, Dialysis and Transplantation Journal*. 24(2), 158–161
- Guyton & Hall, J.E. 2008. *Buku Ajar Fisiologi Kedokteran*. Edisi 11. Jakarta : EGC
- Held, P.J., Port, F.K., Wolfe, R.A., Stannard, D.C., Daugirdas, J.T., Bloembergen, W.E., Greer, J.W., Hakim, R.M. 1996. The dose of hemodialysis and patient mortality. *Kidney Int*. 50(2):550
- Hsu, H-J., Yen, C-H., Wu, I-W., Hsu, K-H., Chen, C-K. 2014. The Association of Uremic Toxins and Inflammation in Hemodialysis Patients. *PLoS ONE*. 9(7): e102691. doi:10.1371/journal.pone.0102691
- Imtiaz, F., Shafique, K., Mirza, S.S., Ayoob, Z., Vart, P. & Rao, S. 2012. Neutrophil lymphocyte ratio as a measure of systemic inflammation in prevalent chronic diseases in Asian population, *International Archives of Medicine*. 5:2, p.1-6
- Indonesian Renal Registri (IRR). 2018. 11th on Report Indonesian Renal Registry.

- Inrig, J.K., Bryskin, S.K., Patel, U.D., Arcasoy, M., Szczech, L.A. 2011. Association between high-dose erythropoiesis-stimulating agents, inflammatory biomarkers, and soluble erythropoietin receptors. *BMC Nephrol.* 12:67
- International Society of Nephrology/ISN. 2012. Kindey disease improving global outcome: Clinical practice guideline for anemia in chronic kidney disease. *Kidney International Supplements.* 2: 283-335
- Irving, K., David, S., Marina, M. 2010. A unifying biologic explanation for “high-sensitivity” Creactive protein and “low-grade” inflammation. *Arthritis Care and Research.* 62(4):442–6
- Kanbay, M., Perazella, M.A., Kasapoglu, B., Koroglu, M., Covic, A. 2010. Erythropoesis stimulatory agent-resistant anemia in dialysis patients: review of causes and management. *Blood Purif.* 29:1-12
- Kalantar-Zadeh, K., Don, B.R., Rodriguez, R.A., Humphreys, M.H. 2001. Serum ferritin is a marker of morbidity and mortality in hemodialysis patients. *Am J Kidney Dis* ;37:564- 572
- Kalantar-Zadeh, K., Ikizler, T.A., Block, G., Avram, M.M., Kopple, J.D. 2003. Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. *Am J Kidney Dis.* 42:864-881
- Kalantar-Zadeh, K., Lee, G.H., Miller, J.E., Streja, E., Jing, J., Robertson, J.A. 2009. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. *Am J Kidney Dis.* 53:823–34
- KDIGO. 2012. KDIGO clinical practice guideline for anemia in chronic kidney disease. *Kidney International Supplements.* 2
- KDOQI. 2007. Clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: update of hemoglobin target. *Am J Kidney Dis.* 50: 471-530
- Kiss, Z., Ambrus, C., Kulcsár, I. 2015. Effect of angiotensin-converting enzyme gene insertion/deletion polymorphism and angiotensin-converting enzyme inhibition on erythropoiesis in patients on haemodialysis. *J Renin Angiotensin Aldosterone Syst.* 16:1021
- Krause, A., Neitz, S., Magert, H.J., Schulz, A., Forssmann, W.G., Schulz-Knappe, P., Adermann, K. 2000. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. *FEBS Lett.* 480: 147–150
- Lacombe, C. 1996. Resistance to erythropoetin. *N Engl J Med.* 334:660-2
- Liu, C. C., Ko, H. J., Liu, W. S., Hung, C. L., Hu, K. C., Yu, L. Y., & Shih, S. C. 2019. Neutrophil-to-lymphocyte ratio as a predictive marker of metabolic syndrome. *Medicine (United States).* 98(43)
- Locatelli, F., Aljama, P., Bárány, P., Canaud, B., Carrera, F., Eckardt, K.U., Hörl, W.H., Macdougall, I.C., Macleod, A., Wiecek, A., Cameron, S. 2004. European best practice huidelines working hroup: revised european best practice guidelines for the management of anaemia in patients with chronic renal failure. *Nephrol Dial Transplant.* 19(suppl 2):ii1–ii47

- Lopez-Gomez, J.M., Portoles, J.M., Aljama, P. 2008. Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality. *Kidney Int Suppl.* S75–81
- López-Novoa, J.M., Rodriguez-Perla, A.B., Ortiz, A., Martinez Salgado, C. and Lopez-Hernandez, F.J. 2011. ‘Etiopathology of chronic tubular, glomerular and renovascular nephropaties: clinical implications’. *Journal of Translational Medicine.* 9:13
- Lubis, A.R. & Siregar, J.H. 2016. Anemia pada penyakit ginjal kronik. Divisi ginjal dan hipertensi Bagian Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Sumatera Utara, diambil dari: <https://repository.usu.ac.id/>
- Macdougall, I.C. 2009. Development of recombinant erythropoietin and erythropoietin analogs. In: Singh, AK and Williams, GH, editors. *Textbook of Nephro-Endocrinology.* Elsevier; Amsterdam: 35-46
- Macdougall, J.C. & Eckardt, K.U. 2010. Anemia in Chronic Kidney Disease. In Floege J, Johnson RJ, Feehally J. editors. *Comprehensive Clinical Nephrology.* 4th ed. Elsevier Saunders; Philadelphia:951-958
- MacGinley, R.J., Walker, R.G. 2013. International treatment guidelines for anaemia in chronic kidney disease: what has changed?. *MJA.* Vol 199 (2)
- Martins, E. C., Da Fe Silveira, L., Viegas, K., Beck, A. D., Júnior, G. F., Cremonese, R. V., & Lora, P. S. 2019. Neutrophil-lymphocyte ratio in the early diagnosis of sepsis in an intensive care unit: A case-control study. *Revista Brasileira de Terapia Intensiva.* 31(1), 63–70
- McGonigle, R.J., Wallin, J.D., Shaddock, R.K., Fisher, J.W. 1984. Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency. *Kidney Int.* 25: 437–444
- Mastro, L.D. & Venturini, M. 1998. Strategies for the Use of Epoetin Alfa in Breast Cancer Patients. *The Oncologist.* 3(5): 314-8
- Mihai, S., Codrici, E., Popescu, I. D., Enciu, A. M., Albuлесcu, L., Necula, L. G., Mambet, C., Anton, G., & Tanase, C. 2018. Inflammation-related mechanisms in chronic kidney disease prediction, progression, and outcome. *Journal of Immunology Research.* <https://doi.org/10.1155/2018/2180373>
- National Kidney Foundation. 2012. K/DOQI clinical practice guidelines for chronic kidney disease evaluation, classification and stratification. *Am J Kidney Dis.* 39(1):1-24
- National Kidney Foundation. 2006. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. New York, *National Kidney Foundation*
- Nemeth, E., Tuttle, M.S., Powelson, J., Vaughn, M.B., Donovan, A, Ward, D.M., Ganz, T., Kaplan, J. 2004. Hcpidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. *Science.* 306: 2090–2093
- Nowak, K. L., & Chonchol, M. 2018. Does inflammation affect outcomes in dialysis patients? *Seminars in Dialysis.* 31(4), 388–397. <https://doi.org/10.1111/sdi.12686>

- Nugraha, G. 2015. *Panduan Pemeriksaan Laboratorium Hematologi Dasar*. Jakarta: CV Trans Info Medika
- Okuyay, G.U., Salih İnal, S., Öneç, K., Erdem Er, R., Paşaoğlu, O., Paşaoğlu, H., Dericim, U. and Erten, Y. 2013. Neutrophil to lymphocyte ratio in evaluation of inflammation in patients with chronic kidney disease. *Renal Failure*. 35(1): 29–36 doi: 10.3109/0886022X.2012.734429
- Ozturk, S., Turgutalp, K., Arici, M., Odabas, A.R., Altiparmarmak, M.R., Aydin, Z., Cebeci, E., Basturk, T., Saypacaci, Z., Sahin, G., Ozler, T.E., Kara, E., Dheir, H., Eren, N., Suleymanlar, G., Islam, M. *et al.* 2020. Mortality analysis of COVID-19 infection in chronic kidney disease, haemodialysis and renal transplant patients compared with patients without kidney disease: a nationwide analysis from Turkey. *Nephrol Dial Transplant*. 35: 2083–2095
- Patel, S. & Patel, J. 2005. Epoetin alfa. NCBI Bookshelf. *Clin.Nephrol*. 64(2):113-23
- Pourfarziani, V., Ghanbarpour, F., Nemati, E., Taheri, S., & Einollahi, B. 2008. Laboratory variables and treatment adequacy in hemodialysis patients in Iran. *Saudi J Kidney Dis Transpl*. 2(9):842-6
- Pernefri. 2011. *Konsensus Manajemen Anemia Pada Pasien Gagal Ginjal Kronik*. Jakarta-Indonesia
- Pernefri. 2017. *10th Report of Indonesian Renal Registry*. Bandung
- Pineault, J., Lamarche, C., Bell, R., Lafrance, J., Ouellet, G., Leblanc, M., Pichette, V., Bezzaoucha, S., & Vallée, M. 2017. Association of neutrophil-to lymphocyte ratio with inflammation and erythropoietin resistance in chronic dialysis patients, *Canadian Journal of Kidney Health and Disease*. Volume 4: 1–7
- Pranoto, I. 2014. Hubungan antara lama hemodialis dengan terjadinya pendarahan intra serebral. *Tesis*
- Priyadarshi, A. & Shapiro, J.I. 2006. Erythropoietin resistance in the treatment of the anemia of chronic renal failure. *Semin Dial*. 19: 273–278
- Reddan, D.N., Klassen, P.S., Szczech, L.A. 2003. White blood cells as a novel mortality predictor in hemodialysis patients. *Nephrol Dial Transplant*. 18:1167–1173
- Rossert, J., Gassmann-Mayer, C., Frei, D., McClellan, W. 2007. Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients. *Nephrol Dial Transplant*. 22:794–800
- Sanzhes, A.F., Madrigal-Santillan, E., Bautista M., Esquivel-Soto, J., Morales-Gonzalez, Esquivel-Chirino, C., *et. al.* 2011. Inflammation, oxidative stress and obesity. *Int. J. Mol. Sci*. 12:3117-32, doi:10.3390/ijms12053117
- Sasu, B.J., Cooke, K.S., Arvedson, T.L., Plewa, C., Ellison, A.R., Sheng, J., Winters, A., Juan, T., Li, H., Begley, C.G., Molineux, G. 2010. Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. *Blood*. 115: 3616–3624
- Saudan, P., Halabi, G., Perneger, T., Wasserfallen, J-B., Wauters, J-P & Martin, P-Y. 2006. ACE inhibitors or angiotensin II receptor blockers in dialysed patients and erythropoietin resistance. *J Nephrol*. 19(1):91-6

- Singh, A.K., Szczech, L., Tang, K.L., Barnhart, H., Sapp, S., Wolfson M. 2006. Correction of anemia with epoetin alfa in chronic kidney disease. *N Engl J Med* . 355: 2085-98
- Shinzato, T., Abe, K., Furusu, A., Harada, T., Shinzato, K., Miyazaki, M., Kohno, S. 2008. Serum pro-hepcidin level and iron homeostasis in Japanese dialysis patients with erythropoietin (EPO)-resistant anemia. *Med Sci Monit*. 14: 431–437
- Sibbel, S.P., Koro, C.E., Brunelli, S.M., and Cobitz, A.R. 2015. Characterization of chronic and acute ESA hyporesponse: a retrospective cohort study of hemodialysis patients. *BMC Nephrology*. 16:144 doi: 10.1186/s12882-015-0138-x
- Smeltzer, S.C. & Bare, B.G. 2002. *Buku Ajar Keperawatan Medikal Bedah*. Edisi 8, vol 3. Jakarta : EGC
- Suhardjono, Lydia, A., Kapojos, E.J., Sidabutar, R.P. 2001. Gagal Ginjal Kronik dalam *Buku Ajar Ilmu Penyakit Dalam*, Jilid II Edisi 3. Jakarta: FKUI
- Suwitra, K. Penyakit ginjal kronik. In: Sudoyo, A.W., Setiyohadi, B., Alwi, I., Setiati, S. 2014. editors: *Buku Ajar Ilmu Penyakit Dalam*. 6nd ed. Jakarta: Interna Publishing. p.2159-65
- Swartzendrubber, D., Smith, L., Peacock, E., McDillon, D. 2005. Hemodialysis procedures and Complications. <http://www.emedicine.com/med/topic683.htm>
- Syarif, A. 2019. Hubungan antara nilai neutrophyl lymphocyte ratio dengan kadar hemoglobin dan hematokrit pada pemberian eritropoietin pasien chronic kidney disease 5 continous ambulatory peritoneal dialysis. *Thesis*
- Tamhane, U.U., Aneja, S., Montgomery, D., Rogers, E.K., Eagle, K.A., Gurm, H.S. 2008. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. *Am J Cardiol*. 102(6):653–657
- Thaha & Widianana. 2019. The Role of Inflammation in Chronic Kidney Disease, Indonesian Journal of Kidney and Hypertension, *InaKidney*. Vol. II, ed. 3
- Turkmen, K., Guney, I., Yerlikaya, F.H., Tonbul, H.Z. 2012. The relationship between neutrophil-to-lymphocyte ratio and inflammation in end-stage renal disease patients. *Ren Fail*. 34: 155–159
- Weiss, G. & Goodnough, L.T. 2005. Anemia of chronic disease. *N Engl J Med*. Vol. 352(10):1011-23
- Wickman, C. & Kramer, H. 2012. Obesity and kidney disease: potential mechanisms. *Semin Nephrol*. 33(1):14-22
- Wilson, L.M. 2012. Penyakit ginjal kronik. In: Hartanto, H., Susi, N., Wulansari, P., Mahanani, D.A., editors: *Patofisiologi Konsep Klinis Proses-proses Penyakit*. Jakarta, 6:912-45
- Wish, J.B. 2014. Anemia and other hematologic complications of chronic kidney disease in Gilbert, S.J., Weiner, D.E., Gipson, D.S. *et al.* ed. *National Kidney Foundations Primer on Kidney Diseases*. 6 th ed. Elsevier saunders ; 57:497-505

- World Health Organization. Regional Office for the Western Pacific. 2000. The Asia-Pacific perspective: redefining obesity and its treatment. *Sydney: Health Communication Australia*. <https://apps.who.int/iris/handle/10665/206936>
- Yucel, D. 2014. C-Reactive Protein vs. High - Sensitivity C - Reactive Protein: What is the Difference? *Turkish Journal of Biochemistry*. 39(1):43–4. Available from: http://www.journalagent.com/z4/download_fulltext.asp?pdire=tjb&plng=eng&un=TJB-92408
- Zumbrennen, Bullough, Z., Babbit, J.L. 2014. Mechanisms of anemia in PGK. *J Am Soc Nephrol*. 23:263-73
- Zaritsky, J., Young, B., Wang, H.J., Westerman, M., Olbina, G., Nemeth, E., Ganz, T., Rivera, S., Nissenson, A.R., Salusky, I.B. 2009. Hcpidin—a potential novel biomarker for iron status in chronic kidney disease. *Clin J Am Soc Nephrol*. 4: 1051–1056
- Zoccali, C. 2003. Arterial pressure components and cardiovascular risk in end-stage renal disease. *Nephrol Dial Transplant*. 18: 249–252